The FTSE 100 index experienced a 0.1% decline, closing at 10,857.70, largely due to a significant 9.0% drop in AstraZeneca shares. This fall followed reports of potential merger talks with US pharmaceutical giant Bristol-Myers Squibb, a deal estimated to be worth $400 billion. Analysts, including Jefferies' Michael Leuchten and Bank of America's Sachin Jain, expressed skepticism, questioning the necessity of such a merger for AstraZeneca, given its strong growth profile, and suggesting it might signal a lack of confidence in its own drug pipeline. This underperformance put the FTSE 100 out of sync with other European and US markets which saw gains, partially driven by falling oil prices.
Despite the drag from AstraZeneca, other sectors of the UK market performed positively. Lower bond yields boosted housing stocks, with Vistry surging 8.0%, Barratt Redrow gaining 3.8%, and Persimmon increasing 2.2%. The broader market also saw strength in mid-cap and small-cap indices; the FTSE 250 rallied 1.0% to 24,224.77, and the AIM All-Share gained 0.8% to 768.61. These gains were also influenced by a fall in Brent oil prices to $83.92 a barrel, down from $90.12, following comments from US President Donald Trump which eased geopolitical tensions.
Investors are now turning their attention to upcoming corporate earnings reports from major companies like BP, HSBC, and Smith & Nephew, the latter of which advanced 3.3% ahead of its half-year results. Additionally, critical US economic data, including trade balance and labor market surveys, are anticipated. The pound, however, saw a slight dip, trading at $1.3425 against the dollar, down from $1.3463 at the close of Friday's equities trading.
